Rafael Holdings, Inc. (NYSE:RFL) Sees Significant Increase in Short Interest

Posted by Latisha Jones on Sep 15th, 2026

Rafael Holdings, Inc. (NYSE:RFL – Get Free Report) was the target of a large increase in short interest in August. As of August 31st, there was short interest totaling 789,900 shares, an increase of 97.7% from the August 15th total of 399,613 shares. Based on an average trading volume of 124,437 shares, the short-interest ratio is currently 6.3 days. Approximately 2.3% of the company’s stock are sold short.

Hedge Funds Weigh In On Rafael

A hedge fund recently bought a new stake in Rafael stock. Kahn Brothers Group Inc. bought a new position in Rafael Holdings, Inc. (NYSE:RFL – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 150,493 shares of the company’s stock, valued at approximately $494,000. Kahn Brothers Group Inc. owned about 0.29% of Rafael at the end of the most recent reporting period. Institutional investors own 11.30% of the company’s stock.

Rafael Stock Down 2.3%

RFL traded down $0.05 during trading on Tuesday, hitting $2.13. 25,567 shares of the company traded hands, compared to its average volume of 126,510. The firm has a market cap of $110.76 million, a P/E ratio of -3.13 and a beta of 0.40. The stock’s fifty day moving average is $2.21 and its 200 day moving average is $1.83. Rafael has a one year low of $1.12 and a one year high of $3.96.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rafael in a research note on Tuesday, August 25th. Wall Street Zen raised shares of Rafael to a “hold” rating in a research report on Saturday, July 25th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Check Out Our Latest Stock Report on Rafael

Rafael Company Profile

(Get Free Report)

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.